S-Biomedic Completes Series A Round With DSM Venturing

S-Biomedic, a pioneer in patented human microbiome skin applications, announces the successful completion of their second Series A financing round.

The second closing welcomed a new investor, DSM Venturing and was also supported by existing shareholder investiere.ch, the leading Swiss VC platform.

In total, S-Biomedic raised €4 million in this Series A. The first tranche was led by skin care global player Beiersdorf. S-Biomedic also secured an investment from investiere.ch, as well as previous contributions from Johnson & Johnson Innovation – JJDC, Inc. The total sum raised will enable S- Biomedic to rapidly progress their portfolio of products and enter into development and commercialisation agreements with leading dermatological and cosmetic brands.

“S-Biomedic have a novel platform technology supported by fundamental insight into the skin microbiome, with promising products in the pipeline. They have a track record of partnering with leading dermatological and cosmetic companies, and clear paths to market”,

explains Rob Beudeker, Investment Director at DSM Venturing.

“We’re delighted to gain another significant investor with DSM, who have a reputation for quality and innovation in active ingredient industry. We’re now entering into discussions with partners around the world, to develop and commercialise our portfolio. We are focussed on bringing our innovative human microbiome products to people who suffer from skin problems”,

comments Veronika Oudova,CEO of S-Biomedic.